New twist in Fortis fight: Renuka Ramnath resigns from panel reviewing offers

A member of the external expert committee set up by the Fortis board to review offers for the company has resigned a day before the committee was to table its report of recommendations to the board. The reasons for this resignation are not clear at this point in time.

Multiples Equity founder Renuka Ramnath submitted her resignation from the expert advisory committee “due to her pre-occupation,” Fortis Healthcare told the Bombay Stock Exchange late on Wednesday.

“The same will be tabled before the board at the scheduled meeting on April 26, 2018 for their consideration and vacancy so caused shall be filled, by the board of directors, with a person of eminent repute,” Fortis stated.

Ramnath, who was the former MD and CEO of ICICI Venture, was to be part of a three member committee chaired by former PwC India CEO Deepak Kapoor. Lalit Bhasin, President, Society of Indian Law Firms and managing partner at Bhasin & Co is the third member of this committee.

The advisory panel was expected to review binding offers submitted by Manipal-TPG, Hero Enterprise Investment Office-Burman Family Office, IHH Healthcare Bhd and Radiant Life Care-KKR by April 25.

The committee’s recommendations would not be binding in nature but the Fortis board was expected to use this report to decide its further course of action in closing a deal.

While Fortis stated it received Ramnath’s resignation on April 25, it is not clear whether she had submitted her resignation on that date.

  • Related Posts

    Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

    Bharat Mandapam witnessed Spectacle of Crazy Innovations by Maker of Ssi Mantra, Best in class Surgical Robot New Delhi: It was a veritable display of innovative potential and prowess of…

    On World Health Day ‘CAHO Na Patient Se Pyaar Hai’

    Chennai hosts 3 Day International Conference CAHOCON on Patient Safety in Hospitals starting April 10 New Delhi:  Patient safety in hospitals is a global concern, more so in India. It…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India